Phio Pharmaceuticals (PHIO) EBITDA Margin (2012 - 2019)
Phio Pharmaceuticals' (PHIO) quarterly EBITDA Margin came in at 10219.05% in Q1 2019, down 48427.0% YoY from N/an in Q1 2018, and down 290.41% on a QoQ basis from 2617.54% in Q3 2018.
Phio Pharmaceuticals (PHIO) EBITDA Margin (2012 - 2019) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 8 years of EBITDA Margin data on file, last reported at 10219.05% in Q1 2019.
- Quarterly EBITDA Margin fell 48427.0% year-over-year to 10219.05% in Q1 2019, while the trailing twelve-month figure through Dec 2019 was 42795.24% (down 3745901.0% YoY) and the FY2019 annual result came in at 42795.24%, down 3745901.0% from the prior year.
- EBITDA Margin eased to 10219.05% in Q1 2019, from 2617.54% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2617.54% in Q3 2018 to a low of 24611.11% in Q2 2016.
- A 5-year average of 11855.58% and a median of 9976.92% in 2018 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2016 — EBITDA Margin sank 1378529 bps — and 2019, when it slumped 48427 bps.
- Tracing PHIO's EBITDA Margin over 5 years: stood at 8664.71% in 2015, then sank by 184 bps to 24611.11% in 2016, then soared by 46 bps to 13273.33% in 2017, then surged by 80 bps to 2617.54% in 2018, then tumbled by 290 bps to 10219.05% in 2019.
- The last three EBITDA Margin figures came in at 10219.05% (Q1 2019), 2617.54% (Q3 2018), and 3274.14% (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -10,219.05% |
| Sep 30, 2018 | -2,617.54% |
| Jun 30, 2018 | -3,274.14% |
| Mar 31, 2018 | -9,734.78% |
| Dec 31, 2017 | -13,273.33% |
| Jun 30, 2016 | -24,611.11% |
| Mar 31, 2016 | -22,450.00% |
| Mar 31, 2015 | -8,664.71% |
| Dec 31, 2014 | -16,471.43% |
| Sep 30, 2014 | -13,806.25% |
| Jun 30, 2014 | -16,841.67% |
| Mar 31, 2014 | -7,896.55% |
| Dec 31, 2013 | -8,682.76% |
| Sep 30, 2013 | -2,251.09% |
| Jun 30, 2013 | -873.33% |
| Mar 31, 2013 | -27,158.49% |
| Dec 31, 2012 | -4,280.00% |
| Sep 30, 2012 | -2,975.44% |